+1 (949) 224 3849

Medias.

"Over the years, I have followed the progress of Rajiv Datar, PhD and have been impressed with his abilities to bring people and teams together to address bioproduct development and production issues and provide the necessary leadership. These skills should be particularly important as the Company develops strategies for bringing biobetter products to the market and I am very pleased to be associated with the company as a Member of its Board."

Dr. Pete Fernandes

In The News...

XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel Inflammasome-Directed Therapeutics Using PASylation Platform February 26th 2020

View Article

DNX Biopharmaceuticals Announces Collaboration with Lung Cancer Initiative at Johnson &Johnson February 18th 2020

View Article

Lung Cancer Innovation QuickFire Challenge - Challenge | JLABS August 2019

View Article

DNX is now Proudly Incubating at EvoNexus in La Jolla, CA May 15th 2016

Since it opened [seven years ago] EvoNexus has given 134 companies a jump-start in its three locations ? downtown San Diego, University City and Irvine. These firms have raised $297 million in angel and venture capital equity funding. Seventeen startups have been acquired, pushing the total "outcomes" for EvoNexus companies ? money raised plus the amount paid by acquirers ? to more than $1 billion. While there are more than two dozen incubators, accelerators and co-working office spaces available to help San Diego startups, EvoNexus has grown into the big dog. As such, it is a key component in the region's efforts to position itself as an alternative to the increasingly congested and expensive Silicon Valley for startups. View Article

DNX Biopharmaceuticals, Inc. and XL-protein GmbH Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals. February 1st 2016

IRVINE, Calif., and FREISING, Germany, Feb. 1, 2016 /PRNewswire-iReach/ -- On June 30, 2015, DNX Biopharmaceuticals ("DNX") of Irvine, California and XL-protein GmbH ("XLp") of Freising, Germany, announced they would collaborate in the development and commercialization of novel long acting biopharmaceutical products with financial terms undisclosed. Under this strategic collaboration, XLp contributes its half-life extension platform technology (PASylation?) and certain molecules that have completed in vivo efficacy proof-of-concept and preclinical studies, and DNX adds its pipeline of candidate molecules for development and commercialization to address a range of unmet needs in Immunology, Metabolism and Ophthalmology. View Article

DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products.   June 30th 2015

IRVINE, Calif. and FREISING, Germany, June 30, 2015 /PRNewswire-iReach/ -- DNX Biopharmaceuticals, Inc. ("DNX") a company with a team of experienced industry professionals with a long and successful track record of developing and manufacturing biopharmaceutical products, and XL-protein GmbH ("XLp"), a leader in protein engineering and modification technologies, today announced a collaboration for the development and commercialization of novel, long-acting biopharmaceutical products. Under this strategic collaboration, XLp will contribute its half-life extension platform technology (PASylation?) and certain molecules that have completed in vivo efficacy proof-of-concept and preclinical studies, and DNX will add its pipeline of candidate molecules for development and commercialization to address a range of unmet needs in Immunology, Metabolism and Ophthalmology. View Article